Pharmacologic treatment options for neonatal seizures have expanded over the past 2 decades, and there is no consensus on optimal treatment strategy. We systematically reviewed the published literature to determine which medication(s) are most effective for treating neonatal seizures, by retrieving trials and observational investigations via PubMed (through August 2011) that focused on pharmacological seizure treatment of neonates ( 28 days old) and utilized continuous or amplitude-integrated EEG to confirm seizure diagnosis and cessation. Our search identified 557 initial articles and 14 additional studies after reference reviews, with 16 meeting inclusion criteria. Of these, 2 were randomized trials and only 3 additional investigations included comparison groups. We found limited evidence regarding the best pharmacologic treatment for neonatal seizures, but were able to devise a treatment algorithm from available data. These findings have the potential to serve as a clinical reference and to inform the design of comparative effectiveness investigations for neonatal antiepileptics.
Treatment options for neonatal seizures remain limited despite their relatively common occurrence (2-4 per 1000 North American births, 19-58 per 1000 in < 1500 gram birth weight infants:), 1-3 even with the introduction of several new antiepileptic medications over the past 2 decades. In addition, there is significant variation in approach to the treatment of neonatal seizures, both in medication choice and in when, or whether, to treat. [4] [5] [6] [7] Phenobarbital and phenytoin/fosphenytoin have traditionally been the most commonly used medications to treat neonatal seizures, despite only approximately 50% efficacy. 8 In addition, concern exists for short-term side effects, medication interactions, the need for frequent blood-level monitoring, and potentially negative neurodevelopmental consequences. [9] [10] [11] Perhaps due to these limitations, the use of other antiepileptic medications is increasingly being reported. Silverstein and Ferriero's 2008 survey of pediatric neurologists found that 73% reported use of levetiracetam and/or topiramate in the treatment of neonatal seizures. 7 Reasons for choosing these antiepileptics included fewer adverse effects and ease of use. 7 We conducted a systematic review to examine the published evidence regarding pharmacological therapy for neonatal seizures. Our objective was to determine which antiepileptic medication or medications are most effective for treating neonatal seizures, to guide development of an evidence-based treatment algorithm to reduce variation among providers, and to inform the design of future investigations to determine the comparative effectiveness of antiepileptics in neonates.
Methods
The systematic review was conducted following the general principles published by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Institute of Medicine Standards for Systematic Reviews. 12, 13 Although randomized controlled trial study designs provide the most internal validity for examining treatment efficacy, previous Cochrane reviews have shown limited randomized controlled trial evidence on this topic. 5 Given the lack of robust randomized controlled trial evidence, we included observational investigations in our systematic review and focused on highlighting the strengths and methodological limitations of each included study.
We searched MEDLINE via PubMed from inception to August 2011. A librarian trained in literature search strategies assisted us in the design of our search terms, which were subsequently reviewed by a second librarian. The search was limited to humans and English language articles and included the specific search terms: National Library of Medicine Medical Subject Heading [MeSH] term ''Seizures/therapy'' AND (''Infant, Newborn''[Mesh] OR neonat*) AND (Humans[Mesh] AND English [lang] ). On reviewing references from articles in the original search, we included additional relevant articles that met our inclusion criteria.
Inclusion and Exclusion Criteria
We only included articles that focused on pharmacological seizure treatment of neonates, defined as infants less than or equal to 28 days postnatal age. Since neonatal seizures are often misdiagnosed by clinical impression alone, we required that seizure diagnosis and cessation of ongoing seizures be confirmed by continuous electrophysiologic monitoring (conventional electroencephalogram (EEG) or amplitude-integrated EEG (aEEG). [14] [15] [16] Case reports, review articles with no primary data, and non-peer-reviewed studies including meeting abstracts were excluded, as were articles that did not include seizure cessation as an outcome. Whenever an investigation included other childhood age groups without neonatal-specific outcomes or failed to report medication dosages, it was also excluded. We did not include articles with a primary focus on seizures due to metabolic disorders (eg, pyridoxine deficiency, nonketotic hyperglycinemia), electrolyte disturbances (eg, correctable hypocalcemia, hypoglycemia), or opioid withdrawal since seizures secondary to these disorders have very specific treatments/prognoses. Studies that focused on benign neonatal convulsions (''fifth-day fits'') were not analyzed since short-term seizure cessation was not likely reflective of pharmacological effectiveness, but rather the natural disease course.
Data Extraction and Quality Assessment
Two authors independently reviewed each title and abstract to determine eligibility. Whenever the abstract did not reveal sufficient information about the study design, the full article was retrieved for review. All 3 authors reviewed all articles that were deemed potentially eligible following abstract review using a structured checklist to evaluate study design, methods, results, potential for study bias, and adverse events. When there was uncertainty about inclusion of an article, it was discussed by all authors and a consensus was achieved.
Data Synthesis
The investigations were divided into 2 tiers based on their study design. Investigations that included a control/comparison group were placed into Tier I. Since the literature on neonatal seizure treatment is limited, we chose to construct and present a Tier II for investigations otherwise meeting the inclusion criteria, but without a comparison group against which the effectiveness of the treatment might be judged. No quantitative synthesis (meta-analysis) was attempted due to the large degree of heterogeneity and design weaknesses of included studies.
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Results
Our MEDLINE search identified 557 articles. After reviewing titles and abstracts and eliminating articles that did not fulfill inclusion criteria, all 3 authors reviewed the full texts of the 64 remaining articles. Review of the references from these publications, yielded 14 additional articles for review. On review of these 78 full texts, a total of 16 investigations utilized EEG for seizure diagnosis and treatment monitoring and otherwise met all inclusion criteria. 8, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In all, 5 studies contained control or comparison groups by design and were designated as Tier I investigations (Table 1) . 8, [17] [18] [19] [20] Only 2 of these investigations, a comparison of phenobarbital to phenytoin by Painter et al 8 and a comparison of lidocaine versus benzodiazepines as second-line therapy by Boylan et al 17 , were randomized trials. A total of 11 additional studies meeting inclusion criteria, but without comparison groups, were placed into Tier II ( Table 2) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Of the Tier I investigations, Painter et al's study 8 was the only one to focus on phenobarbital and phenytoin. The wellconstructed trial randomized 59 patients to receive phenobarbital to a goal free level of 25 mg/mL or phenytoin to a free level of 3 mg/mL, with crossover to the alternate therapy if the first failed. Continuous EEG was utilized. Seizures were initially controlled in 43% of term and preterm infants with phenobarbital and 45% with phenytoin (P ¼ 1), and ultimate seizure control was obtained after crossover in 57% and 62%, respectively (P ¼ .67). Overall, phenobarbital and phenytoin were equally effective. If one considers ''substantial improvement'' (80% seizure reduction) rather than complete seizure cessation, these efficacy rates improve to 80% and 72% (P ¼ .3), respectively. No serious adverse events were observed. Although the patients were randomized, this study did have some minor limitations. It was a single-center study, there was some imbalance in baseline characteristics between groups, and it was only single blinded, as physicians and EEG technicians were aware of treatment assignment.
Other Tier I investigations focused on lidocaine and/or midazolam as second-or third-line after phenobarbital failure. 
Investigations Without Comparison Groups (Tier II)
In the 11 studies placed into Tier II ( Table 2) for lack of a comparison group, a wide variety of agents were used, including phenobarbital, phenytoin, lorazepam, paraldehyde, thiopental, midazolam, lidocaine, and levetiracetam. In many cases, the agents under investigation were used second-or third-line. Some investigations only recorded continuous EEG for a portion of subjects. If grouped by evidence for each particular antiepileptic agent, the following results can be summarized.
a. Phenobarbital-Connell et al 22 reported complete response in 2 of 31 (6%) patients given phenobarbital 20 mg/kg as first-line treatment. Bye and Flanagan's 1995 investigation 25 to assess spatial and temporal characteristics of seizures, utilized a seizure-treatment protocol that began with phenobarbital up to 40 mg/kg, or a serum level of 40 mg/mL, and they documented sustained seizure cessation, achieved within 120 minutes in 8 of 32 (25%) patients, after phenobarbital alone. Boylan et al 27 had 4 of 14 (29%) patients responding to a first phenobarbital load of 20 mg/kg. Of the 4, 2 had sustained seizure freedom and 2 had brief seizure recurrence within a few days. They reported that responders tended to display low seizure burden and normal or only mildly abnormal EEG background. b. Phenytoin-Bye and Flanagan's 1995 study 25 
Discussion
There is limited evidence regarding the best pharmacologic treatment for neonatal seizures. Of the 2 randomized trials 8, 17 included in our review, only 1 was large enough to enable statistical analysis. 8 Only 3 other studies, including a prospective nonrandomized experimental study 18 and 2 retrospective cohort investigations 19, 20 allow comparison of between-group treatment effects. Previous investigations of neonatal seizure treatment were groundbreaking in their descriptions of the first exposures of seizing infants to novel medications. However, determining the risks and benefits of the antiepileptic drugs from much of the existing data is limited by study design, including the lack of a comparison/control group. Despite this limited evidence, we present a hierarchy of treatment options based on the current literature (Figure 1 ). We include considerations of practicality and patient safety in our rankings.
We recommend phenobarbital as first-line treatment given its inclusion in the only randomized controlled trial of firstline treatment of neonatal seizure, 8 the fact that it is the most studied antiepileptic medication in animals, 32 and its historical precedence as the first-line antiepileptic drug for neonates. 32 We caution that there is extremely limited evidence on the effect of phenobarbital on long-term neonatal neurodevelopment. Safety considerations severely limit its use in older populations and the US Food and Drug Administration (FDA) has never approved phenobarbital for use in any patient population. 33 Nonetheless, no neonatal antiepileptic has been shown superior to phenobarbital in a well-designed investigation. Although phenytoin was found to be equally effective by Painter et al, 8 the potential for side effects, the unpredictability of metabolism in neonates, and the need for frequent bloodlevel monitoring prevent us from recommending it as a firstline option.
Levetiracetam, phenytoin/fosphenytoin, and lidocaine all appear potentially effective as second-line treatments for neonatal seizures that are unresponsive to phenobarbital. Based on our systematic review findings alone, there is not strong evidence to recommend the use of any one of the medications over the others for second-line seizure control.
Lidocaine appears effective compared to benzodiazepines, but has a narrow therapeutic window and the potential to cause cardiac arrhythmias or hypotension, and can induce seizures at high doses. [34] [35] [36] Lidocaine should also not be given following fosphenytoin/phenytoin because they may have additive cardiodepressive effects. 37 Phenytoin/fosphenytoin was shown to only provide about a 10% to 15% increase in seizure control when given following phenobarbital failure. 8 It also requires frequent blood-level monitoring, and is not an ideal medication for maintenance at discharge given its erratic oral absorption, frequency of dosing (usually every 6-8 hours), and continuing drug metabolism changes in young infants. 8, 38, 39 Blood loss due to therapeutic drug monitoring may be benign in older patients, but is potentially harmful and increases the risk of transfusion and associated morbidities/mortality in neonates whose blood volumes average 80 mL/kg. [40] [41] [42] [43] [44] [45] Levetiracetam appeared to acutely reduce seizure burden in 2 separate studies, but there were no within-study comparison groups. 30, 31 It does not require blood-level monitoring, is easily continued as outpatient therapy, and is one of the few Food and Drug Administration-approved antiepileptics for children as young as one-month of age. 46 For these reasons, and given the limitations of lidocaine and fosphenytoin/phenytoin, it is often the preferred second-line treatment at our institution. However, we caution that that its efficacy and safety profile has not been adequately studied in term or preterm neonates within the first month of life. When used, we suggest dosing of 40-50 mg/kg bolus in line with Khan et al's study, 31 which showed good rapidity of response without any significant side effects.
Although Castro-Conde et al 19 found better seizure reduction with second-line midazolam than historically matched phenobarbital nonresponders, Shany et al's cohort study 20 and Boylan et al's trial 17 found it inferior to lidocaine. A serious side effect of benzodiazepines including midazolam is sedation, 19 potentially leading to respiratory depression and intubation. 47, 48 Still, midazolam may be considered as a second-or third-line therapy choice, especially in already intubated neonates.
No articles on treatment options, including pentobarbital coma, for infants in status epilepticus met our inclusion criteria. Therefore, we have no reason to recommend against a trial of pentobarbital in intubated patients following failure of other pharmacological therapies. A trial of lidocaine may also be considered in this grave situation if phenytoin was not previously given. 37 We excluded pyridoxine-deficiency from our review but remind the reader to consider pyridoxine challenge when other antiepileptics provide no response.
A key finding of our systematic review is that well-designed research investigations are clearly needed to determine which antiepileptic medication or medications are most effective for treating neonatal seizures. There are minimal data for many antiepileptics including topiramate, which is being increasingly used in neonates. Future studies should include verification of seizure diagnosis and cessation via conventional or amplitudeintegrated EEG and, when feasible, focus on similar seizure etiologies and patients. 32, 49 Randomized controlled trials provide the most unbiased estimates of treatment effects, but have proven demanding due to expense, the need for cooperation between multiple neonatal centers to ensure adequate statistical power, and reports of difficulty enrolling neonates in clinical trials of anticonvulsants, at least partially due to parental apprehension about randomization and blinding of treatment. 16, 50 A comprehensive cohort design, in which infants whose parents decline randomization are still enrolled in a prospective cohort, is a potential solution that is being increasingly used by clinical investigators. 51 Existing collaborative multicenter networks have the potential to play a critical role in funding and conducting neonatal seizure treatment trials 52, 53 and further collaboration among institutions remains imperative for trial success.
Although prone to confounding by indication, welldesigned observational studies also have a critical role to play in neonatal seizure therapy research. Carefully constructed prospective and retrospective cohort investigations could discover treatment associations that will inform both clinical practice and the design of future trials. In addition, large observational databases are perhaps the ideal tool to study rare but potentially harmful drug side effects. 54, 55 
Conclusion
There is limited evidence regarding the best pharmacologic treatment for neonatal seizures. We anticipate that this systematic review of neonatal seizure treatment will serve as a valuable reference that will aid clinicians and inform the design of future investigations to compare the effectiveness of neonatal antiepileptics. Further research is needed not only to determine which antiepileptic medication is most effective in neonates but also to verify the safety of treating neonates with these medications.
